Stock ALGS ALIGOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-10 EDT 		5-day change 1st Jan Change
0.7303 USD -5.95% Intraday chart for Aligos Therapeutics, Inc. -9.85% +9.98%
04-03 Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects CI
03-27 Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
GL
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
GL
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
AQ
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
AQ
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
GL
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
GL
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
AQ
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
GL
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
GL
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
AQ
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
GL
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
GL
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
AQ
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
GL
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
GL
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
GL
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
GL
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
GL
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
AQ
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALGS Stock
  4. News Aligos Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW